Envestnet Asset Management’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-24,998
| Closed | -$427K | – | 4672 |
|
|
2025
Q2 | $427K | Sell |
24,998
-12,361
| -33% | -$527K | ﹤0.01% | 3815 |
|
|
2025
Q1 | $2.38M | Sell |
37,359
-8,255
| -18% | -$869K | ﹤0.01% | 2606 |
|
|
2024
Q4 | $5.55M | Buy |
45,614
+4,847
| +12% | +$594K | ﹤0.01% | 2035 |
|
|
2024
Q3 | $5.09M | Sell |
40,767
-27,912
| -41% | -$3.86M | ﹤0.01% | 2091 |
|
|
2024
Q2 | $10.9M | Buy |
68,679
+28,073
| +69% | +$3.61M | ﹤0.01% | 1499 |
|
|
2024
Q1 | $5.26M | Buy |
40,606
+8,241
| +25% | +$1.01M | ﹤0.01% | 1940 |
|
|
2023
Q4 | $3.12M | Sell |
32,365
-3,277
| -9% | -$314K | ﹤0.01% | 2197 |
|
|
2023
Q3 | $4.32M | Buy |
35,642
+21,514
| +152% | +$2.43M | ﹤0.01% | 1897 |
|
|
2023
Q2 | $1.62M | Buy |
14,128
+3,108
| +28% | +$401K | ﹤0.01% | 2413 |
|
|
2023
Q1 | $1.52M | Buy |
11,020
+3,574
| +48% | +$464K | ﹤0.01% | 2378 |
|
|
2022
Q4 | $965K | Buy |
7,446
+1,240
| +20% | +$144K | ﹤0.01% | 2675 |
|
|
2022
Q3 | $686K | Buy |
6,206
+3,144
| +103% | +$317K | ﹤0.01% | 2826 |
|
|
2022
Q2 | $230K | Sell |
3,062
-2
| -0.1% | -$147 | ﹤0.01% | 3503 |
|
|
2022
Q1 | $239K | Sell |
3,064
-329
| -10% | -$25.2K | ﹤0.01% | 3577 |
|
|
2021
Q4 | $306K | Sell |
3,393
-1,004
| -23% | -$85.8K | ﹤0.01% | 3402 |
|
|
2021
Q3 | $407K | Buy |
4,397
+874
| +25% | +$67.3K | ﹤0.01% | 3103 |
|
|
2021
Q2 | $274K | Sell |
3,523
-1,694
| -32% | -$128K | ﹤0.01% | 3340 |
|
|
2021
Q1 | $389K | Sell |
5,217
-4,083
| -44% | -$377K | ﹤0.01% | 2994 |
|
|
2020
Q4 | $1.59M | Buy |
9,300
+115
| +1% | +$17K | ﹤0.01% | 1906 |
|
|
2020
Q3 | $1.29M | Buy |
9,185
+5,708
| +164% | +$867K | ﹤0.01% | 1867 |
|
|
2020
Q2 | $558K | Sell |
3,477
-18
| -0.5% | -$2.45K | ﹤0.01% | 2359 |
|
|
2020
Q1 | $342K | Buy |
3,495
+196
| +6% | +$22.4K | ﹤0.01% | 2489 |
|
|
2019
Q4 | $426K | Sell |
3,299
-725
| -18% | -$73.2K | ﹤0.01% | 2548 |
|
|
2019
Q3 | $303K | Buy |
4,024
+1,034
| +35% | +$122K | ﹤0.01% | 2666 |
|
|
2019
Q2 | $454K | Sell |
2,990
-626
| -17% | -$76.1K | ﹤0.01% | 2445 |
|
|
2019
Q1 | $431K | Buy |
3,616
+535
| +17% | +$68.8K | ﹤0.01% | 2435 |
|
|
2018
Q4 | $336K | Buy |
+3,081
| New | +$385K | ﹤0.01% | 2367 |
|
|
2018
Q3 | – | Sell |
-1,021
| Closed | -$135K | – | 2430 |
|
|
2018
Q2 | $135K | Buy |
1,021
+13
| +1% | +$1.23K | ﹤0.01% | 1876 |
|
|
2018
Q1 | $75K | Sell |
1,008
-82
| -8% | -$5.47K | ﹤0.01% | 2005 |
|
|
2017
Q4 | $61K | Buy |
1,090
+60
| +6% | +$3.18K | ﹤0.01% | 2261 |
|
|
2017
Q3 | $47K | Buy |
1,030
+459
| +80% | +$18.3K | ﹤0.01% | 2299 |
|
|
2017
Q2 | $20K | Buy |
571
+158
| +38% | +$5.14K | ﹤0.01% | 2595 |
|
|
2017
Q1 | $13K | Sell |
413
-162
| -28% | -$5.01K | ﹤0.01% | 2744 |
|
|
2016
Q4 | $16K | Buy |
+575
| New | +$23.1K | ﹤0.01% | 2699 |
|
Other funds holding SRPT
EAM
Envestnet Asset Management's SRPT Position: Q3 2025 in Review
Envestnet Asset Management sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 24,998 shares — an estimated $427K sold.
Envestnet Asset Management first reported a position in SRPT in Q4 2016 and held it in 34 quarters. The position peaked at $10.9M in Q2 2024. 319 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.
- Envestnet Asset Management reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
- Envestnet Asset Management sold 24,998 Sarepta Therapeutics shares in Q3 2025, an estimated $427K.
- Envestnet Asset Management first reported a position in Sarepta Therapeutics in Q4 2016 and held it in 34 quarters.
- Envestnet Asset Management's Sarepta Therapeutics position peaked at $10.9M in Q2 2024.
- 319 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.
Based on Envestnet Asset Management's 13F filing for Q3 2025, filed 5 Nov 2025.